Cipla share price in focus: Drug major's arm recalls over 400 cartons of cancer drug in the US; check details

Warren (New Jersey)-based Cipla USA, Inc. is recalling Nilotinib Capsules in two strengths (150 mg and 200 mg), the US health regulator said in its latest Enforcement Report.

The company is recalling the affected lot (271 and 164 cartons) due to "failed tablet/capsule specifications", it stated.

Cipla USA, Inc. initiated the Class III voluntary recall on February 18 this year.

According to the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences".

Nilotinib works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

India has the highest number of USFDA-compliant pharmaceutical plants outside of the US.

Indian pharmaceutical companies supply a substantial proportion of drugs to US residents, with four out of 10 of all prescriptions filled in the US in 2022 being supplied by Indian companies.

About Cipla

Cipla Limited is a pharmaceutical company founded in 1935 by Khwaja Abdul Hamied. Headquartered in Mumbai, Cipla is one of the most popular pharma brands in India.

Business operations

Cipla specialises in developing diverse formulations across various sectors in the pharmaceutical industry.

The company's products include drugs for Alzheimer's, arthritis, Parkinson's, and cardiovascular diseases.

In recent times, Cipla has introduced several innovative products. This includes the I-Pill, an oral emergency contraceptive. It also introduced No Touch Breast Scan (NTBS) technology – an advanced, painless, non-invasive, and radiation-free method for early breast cancer detection in India.

Cipla Q3 FY26 Earnings

Drug maker Cipla reported a 57% year-on-year (YoY) dip in consolidated profit after tax (PAT) to ₹676 crore for the third quarter ended December 31, 2025 (Q3 FY26), impacted by a drop in US sales.

The Mumbai-based firm posted a profit after tax of ₹1,571 crore for the October-December quarter last year.

Total income from operations rose to ₹7,074 crore for the period under review as against ₹7,073 crore seen in the year-ago period, Cipla said in a regulatory filing.

The company's North America sales dropped 22% to ₹1,485 crore during the quarter as compared with ₹1,906 crore in the year-ago period.